QAAHBX — T. Rowe Price Health Sciences Portfolio

Data updated: 2026-08-27

QAAHBX — T. Rowe Price Health Sciences Portfolio. United States Large Cap Blend / Core Health Care Equity. Holdings, fees, performance and SEC filings.

QAAHBX Fund Overview

QAAHBX — T. Rowe Price Health Sciences Portfolio is a US mutual fund managed by T. Rowe Price Equity Series, Inc., categorised as United States Large Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.

  • Type: US mutual fund
  • Manager: T. Rowe Price Equity Series, Inc.
  • Category: United States Large Cap Blend / Core Health Care Equity
  • Assets under management: $751.71M
  • 1-year return: 30.1%
  • Ticker: QAAHBX
  • SEC CIK: 0000918294
  • SEC series ID: S000002083
  • Share class ID: C000005449

QAAHBX Holdings

Top 10 holdings of T. Rowe Price Health Sciences Portfolio by percentage of net assets, from the fund's latest SEC N-PORT filing.

Holding% of net assets
Eli Lilly & Co.14.06%
Johnson & Johnson6.64%
Unitedhealth Group, Inc.5.88%
Abbvie, Inc.5.12%
Merck & Co. Inc.4.00%
Gilead Sciences, Inc.2.79%
Thermo Fisher Scientific, Inc.2.53%
Vertex Pharmaceuticals, Inc.2.26%
Bristol-Myers Squibb Co.2.12%
Abbott Laboratories1.91%

View all QAAHBX holdings

QAAHBX Portfolio Allocation

Asset-class allocation of T. Rowe Price Health Sciences Portfolio by percentage of net assets, from the latest SEC N-PORT filing.

Asset classAllocation
Equity99.1%
Cash & Equivalents0.9%
Fixed Income0.1%

QAAHBX Performance

Total returns for QAAHBX (as of 2026-09-01), from SEC filings.

PeriodTotal return
YTD7.1%
1 year30.1%
3 years (annualised)9.2%
5 years (annualised)3.4%

QAAHBX Risk Information

Risk metrics for QAAHBX, derived from monthly returns in SEC filings.

  • 1-year volatility (annualised): 16.1%

QAAHBX Costs and Fees

QAAHBX costs about $111 per $10,000 invested per year in fund expenses.

  • Net expense ratio: 1.11%
  • Gross expense ratio: 1.11%
  • Portfolio turnover: 65%
  • Brokerage commissions: 2.93 bps of average net assets (SEC N-CEN)

QAAHBX Cashflows

Over the 12 months to 2026-06, T. Rowe Price Health Sciences Portfolio had net outflows of $33.99M, from monthly SEC N-PORT filings.

MonthNet flow
2026-06−$1.85M
2026-05−$3.67M
2026-04$122.52K
2026-03−$5.61M
2026-02−$3.45M
2026-01−$13.18M

QAAHBX Debt Constituents

Largest debt holdings of T. Rowe Price Health Sciences Portfolio by percentage of net assets, from the latest SEC N-PORT filing.

Debt holding% of net assets
Immunocore Holdings Cb 2.50% 2/300.09%
Delfi Diagnostics CVT Prom Note PP0.01%
Kartos Therapeutics CVT Prom Note 03/27 PP0.01%
Reflexion Med CVT Note issued 082725 PP0.00%
Reflexion Med CVT Note issued 081325 PP0.00%
Reflexion Med CVT Note issued 072525 PP0.00%
Kartos Therapeutics CVT Note 05/27 PP0.00%

QAAHBX Prospectus and SEC Filings

Official T. Rowe Price Health Sciences Portfolio filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.

Related Funds

Other United States Large Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:

Data Sources

ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.